PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia
Tonya M. Gilbert, … , Joshua L. Roffman, Jacob M. Hooker
Tonya M. Gilbert, … , Joshua L. Roffman, Jacob M. Hooker
Published January 2, 2019; First published December 10, 2018
Citation Information: J Clin Invest. 2019;129(1):364-372. https://doi.org/10.1172/JCI123743.
View: Text | PDF
Categories: Clinical Medicine Neuroscience

PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia

Abstract

BACKGROUND. Patients with schizophrenia (SCZ) experience chronic cognitive deficits. Histone deacetylases (HDACs) are enzymes that regulate cognitive circuitry; however, the role of HDACs in cognitive disorders, including SCZ, remains unknown in humans. We previously determined that HDAC2 mRNA levels were lower in dorsolateral prefrontal cortex (DLPFC) tissue from donors with SCZ compared with controls. Here we investigated the relationship between in vivo HDAC expression and cognitive impairment in patients with SCZ and matched healthy controls using [11C]Martinostat positron emission tomography (PET). METHODS. In a case-control study, relative [11C]Martinostat uptake was compared between 14 patients with SCZ or schizoaffective disorder (SCZ/SAD) and 17 controls using hypothesis-driven region-of-interest analysis and unbiased whole brain voxel-wise approaches. Clinical measures, including the MATRICS consensus cognitive battery, were administered. RESULTS. Relative HDAC expression was lower in the DLPFC of patients with SCZ/SAD compared with controls, and HDAC expression positively correlated with cognitive performance scores across groups. Patients with SCZ/SAD also showed lower relative HDAC expression in the dorsomedial prefrontal cortex and orbitofrontal gyrus, and higher relative HDAC expression in the cerebral white matter, pons, and cerebellum compared with controls. CONCLUSIONS. These findings provide in vivo evidence of HDAC dysregulation in patients with SCZ and suggest that altered HDAC expression may impact cognitive function in humans. FUNDING. National Institute of Mental Health (NIMH), Brain and Behavior Foundation, Massachusetts General Hospital (MGH), Athinoula A. Martinos Center for Biomedical Imaging, National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH Shared Instrumentation Grant Program.

Authors

Tonya M. Gilbert, Nicole R. Zürcher, Christine J. Wu, Anisha Bhanot, Baileigh G. Hightower, Minhae Kim, Daniel S. Albrecht, Hsiao-Ying Wey, Frederick A. Schroeder, Anais Rodriguez-Thompson, Thomas M. Morin, Kamber L. Hart, Amelia M. Pellegrini, Misha M. Riley, Changning Wang, Steven M. Stufflebeam, Stephen J. Haggarty, Daphne J. Holt, Marco L. Loggia, Roy H. Perlis, Hannah E. Brown, Joshua L. Roffman, Jacob M. Hooker

×

Figure 1

Study design.

Options: View larger image (or click on image) Download as PowerPoint
Study design. Subjects with SCZ/SAD were group matched to healthy contro...
Subjects with SCZ/SAD were group matched to healthy controls based on age, sex, smoking status, and parental socioeconomic status (SES). Injected dose and specific activity of [11C]Martinostat did not differ between groups. All subjects underwent a [11C]Martinostat PET scan and cognitive testing with the MCCB. Subjects with SCZ/SAD received the PANSS interview to measure symptom severity.